Welcome to our mini-symposium in Uppsala organized together with Uppsala University and Lund Stem Cell Center

Welcome to our Mini-symposium in Uppsala organized together with Uppsala University and Lund Stem Cell Center.

After high request since our last ATMP Mini-Symposium, we are excited to announce the next edition! Join us at UppsalaUniversity on June 16th for another insightful event. In collaboration with Uppsala University and Lund Stem Cell Center, CCRM Nordic is organizing an ATMP Mini-Symposium featuring a set of exciting presentations.

Date: June 16th, 2025

Location: Gunnesalen Entrance 10, Akademiska Sjukhuset, Uppsala

We are looking forward to hearing from: Magnus Essand Gunilla Enblad Sergey Rodin Per-Ola Carlsson and Karl-Henrik Grinnemo from Uppsala University, Katarina Le Blanc Fredrik Lanner and Antje Zickler from Karolinska Institutet, Henrik Ahlenius Malin Parmar and Anna Falk from Lund Stem Cell Center, Li-Ming Gan from Ribocure Pharmaceuticals AB, Jesper Hedberg from Testa Center and Chao Sheng and Fredrik Wessberg from CCRM Nordic.

Our last ATMPsymposium saw an impressive turnout of over 170 attendees, featuring groundbreaking research from e.g., Peter Zandstra and Johan Ericson and fostering valuable networking within the field – make sure not to miss it!

Sign up here: https://doit.medfarm.uu.se/bin/kurt3/kurt/8885787

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca